Login to Your Account


Clinical Data to Earn up to $252M

CombinatoRx Gains Adenosine Agonist Rights in Surprise Deal

By Catherine Hollingsworth


Friday, August 14, 2009
Clinical Data Inc. entered a collaboration and licensing agreement with CombinatoRx Inc. to develop an adenosine A2A agonist compound in a combination therapy for multiple myeloma and other B-cell cancers, but the deal might be more strategic than lucrative. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription


»

Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
 
For Sales Inquiries:
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Fax: 1-770-810-3145
BioWorld.salessupport@thomsonreuters.com
 
Privacy Policy | Terms of Use
 
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
bioworld.support@thomsonreuters.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
© 2013 Thomson Reuters. Reproduction, reposting content is strictly prohibited.

Free Ezine

Sign up for Perspectives FREE e-mail newsletter

Click here